🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

493 results for “Regeneron UK Limited” Clear

  1. Cemiplimab

    Regeneron UK Limited

    Bladder Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  2. Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]

    Regeneron UK Limited

    Colon Cancer

    phase 2 small molecule active

    1 trial

  3. Cemiplimab 350 MG Intravenous Solution

    Regeneron UK Limited

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  4. Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles

    Regeneron UK Limited

    Merkel Cell Carcinoma, Stage I

    phase 2 small molecule active

    1 trial

  5. Cemiplimab Plus Gemcitabine

    Regeneron UK Limited

    Pancreatic Ductal Adenocarcinoma (mPDAC)

    phase 2 small molecule active

    1 trial

  6. Cemiplimab-Rwlc

    Regeneron UK Limited

    Non-small Cell Lung Cancer Stage III

    phase 2 small molecule active

    1 trial

  7. Cemiplimab-Rwlc

    Regeneron UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

  8. Cemiplimab-Rwlc

    Regeneron UK Limited

    Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule terminated

    2 trials

  9. DB-OTO

    Regeneron UK Limited

    Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

    phase 2 gene therapy active

    1 trial

  10. Degarelix

    Regeneron UK Limited

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  11. Dupilumab

    Regeneron UK Limited

    Pruritis

    phase 2 small molecule active

    1 trial

  12. Dupilumab

    Regeneron UK Limited

    Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  13. Dupilumab

    Regeneron UK Limited

    Peanut Allergy

    phase 2 small molecule completed

    2 trials

  14. Dupilumab

    Regeneron UK Limited

    Atopic Keratoconjunctivitis

    phase 2 small molecule active

    1 trial

  15. Dupilumab

    Regeneron UK Limited

    Eosinophilic Gastritis (EoG)

    phase 2 small molecule active

    1 trial

  16. Dupilumab

    Regeneron UK Limited

    Asthma, Allergic

    phase 2 small molecule active

    1 trial

  17. Dupilumab

    Regeneron UK Limited

    Alopecia Areata

    phase 2 small molecule active

    2 trials

  18. Dupilumab

    Regeneron UK Limited

    Allergies Food Milk

    phase 2 small molecule terminated

    1 trial

  19. Dupilumab

    Regeneron UK Limited

    Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  20. Dupilumab

    Regeneron UK Limited

    Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  21. Dupilumab (blinded)

    Regeneron UK Limited

    Eosinophilic Gastritis

    phase 2 small molecule completed

    1 trial

  22. Dupilumab 300Mg Solution for Injection

    Regeneron UK Limited

    Pruritus

    phase 2 small molecule completed

    1 trial

  23. Dupixent®

    Regeneron UK Limited

    Allergic Rhinoconjunctivitis

    phase 2 mab completed

    1 trial

  24. Encorafenib + Binimetinib

    Regeneron UK Limited

    Melanoma BRAF V600E/K Mutated

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources